You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科济药业下周一起招股,入场费16565港元
生物科技公司科济药业(02171.HK)将于下周一(6月7日)招股,全球发行约9474.7万股,招股价介乎29.6港元至32.8港元,一手500股,入场费16565港元,最多集资31.08亿港元。
预计6月10日截止招股,预计6月18日挂牌。公司过去曾获着名投资者投资,主要股东包括新加坡政府投资公司GIC以及GIC全资子公司Prowell Ventures。截至去年12月底,两间公司各自持有8.81%股权。
承销团之一的高盛早前发表报告预料,公司最快于2023年财年录得销售收入,并给予公司估值介乎348亿元至426亿元。
拥有11条候选管线 但目前未有产品获商业化批准
公司目前已开发11款候选产品的差异化管线,其中6个正处于临床阶段。在11个候选产品中,10个是CAR-T细胞疗法,其中5个处于临床阶段。不过,公司未有任何产品获得商业化销售批准,亦未从任何产品中产生任何收益。
截至最后实际可行日期,科济药业已在中国、美国和加拿大获得7个CAR-T疗法的IND许可。
目前,公司在上海徐汇区已有一个生产厂房,总建筑面积约3000平方米,该厂房的CAR-T的年产能足以支持采用CAR-T治疗200名患者。公司亦已完成位于上海金山区的生产厂房建设,预期该厂房可支持每年采用CAR-T治疗多达2000名患者。根据其全球扩张计划,目前公司正计划建设金山生产厂房II期工程,并在美国建设符合GMP要求的生产厂房,预计产能可支持每年超过10000名患者的治疗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.